Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Solana’s Price Climbs to $151.13 as Caution Flags Appear on Short-Term Charts

Solana’s Price Climbs to $151.13 as Caution Flags Appear on Short-Term Charts

BitgetBitget2025/07/02 04:16
By:Bitget
  • Solana jumped 3.57 percent to $151.13, although the volume saw a 22 percent decrease, indicating a decline in momentum.
  • $152.15 marks immediate resistance, with a potential retracement target near $146.
  • The TD Sequential indicator shows a sell setup as price tests critical Fibonacci levels.

Solana’s trading activity has experienced a drastic change as the price increased to $151.13, a 3.57% increase in 24 hours. The market cap also increased to $80.77 billion, rising by 3.59% within the same duration. While the increase appears impressive, short-term indications point to possible short-term corrections. 

Volume decreased significantly by 22% to $2.45 billion, revealing lesser participation despite the price increase. Analysts are also following closely $152.15 resistance, as technical charts now reflect a potential retracement zone forming close to that price.

Fibonacci Levels and Short-Term Rejection Risks

On the 4-hour chart, Solana has shown clear interaction with Fibonacci retracement levels. The current price action aligns near the 1.0 level at approximately $152.15. That level now acts as resistance. Meanwhile, the TD Sequential indicator flashed a potential sell setup. 

#Solana $SOL could retrace to $146, with the TD Sequential flashing a sell signal! pic.twitter.com/mmHO6dePTE

— Ali (@ali_charts) June 29, 2025

This setup appeared after Solana tested and was briefly rejected near the $152 level. The market’s recent structure confirms that price remains vulnerable to downside pressures. Historical resistance at this level further supports the likelihood of a pullback.

Declining Volume Undermines Bullish Momentum

Despite the steady price climb, the daily volume declined by over 22%. This sharp drop in volume, from a previous higher figure, could weaken upward momentum. Moreover, a lower volume-to-market-cap ratio at 3.03% suggests less aggressive market activity. These dynamics often precede short-term corrections when bullish momentum becomes unsustainable. If the current pattern holds, price may revisit support around $145.97 before establishing the next directional trend.

Retracement Levels May Guide Near-Term Outlook

Support remains anchored at $145.97, a level aligned with the 0.618 Fibonacci line on recent chart patterns. If bearish action unfolds, that area could provide temporary stability. Until Solana breaks decisively above $152.15 with stronger volume, the retracement path toward $146 remains valid. Notably, the upper resistance at $154.68 could serve as the next challenge if bullish strength resumes. For now, Solana’s chart structure shows a temporary cooling phase following its recent gains.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stock IPO Preview | From Losses to Net Profit of 5.46 Million: The "Three-Dimensional" Platform Business Strategy with a Taste for Golf

Crossing the break-even line, the growth inflection point has arrived.

智通财经•2026/11/11 03:22

Core CPI Exceeds Expectations Again, Fed Hawks Loud! 2027 FOMC Voting Member Directly Calls Inflation Hot

Austan Goolsbee, President of the Chicago Federal Reserve, stated that officials must address the issue of high inflation, and described the October consumer price report as worrisome.

智通财经•2026/11/11 03:06

Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality

The FDA requires all GLP-1 drugs to include a warning about the rare eye disease NAION. Novo Nordisk and Eli Lilly deny any causality, while Citi states that the impact on adoption is limited.

智通财经•2026/11/11 02:56
Weight-loss drug receives FDA warning for rare eye disease; Novo Nordisk (NVO.US) and Eli Lilly (LLY.US): No evidence of causality